Porton Biopharma Limited Licenses Erwinase® to Clinigen
Porton Biopharma Limited (PBL), the UK biopharmaceutical research, development and manufacturing company, announces that it has signed an exclusive, worldwide licensing agreement with Clinigen for the distribution of Erwinase®/ Erwinaze®, the company’s life-saving treatment for acute lymphoblastic leukaemia, a cancer of the blood predominantly affecting children.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.